- Home
- PDEX vs SLS Comparison
PDEX vs SLS Comparison
Compare PDEX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- SLS
- Stock Information
- Founded
- PDEX 1978
- SLS 2012
- Country
- PDEX United States
- SLS United States
- Employees
- PDEX N/A
- SLS N/A
- Industry
- PDEX Medical/Dental Instruments
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- SLS Health Care
- Exchange
- PDEX Nasdaq
- SLS Nasdaq
- Market Cap
- PDEX 167.6M
- SLS 169.6M
- IPO Year
- PDEX N/A
- SLS N/A
- Fundamental
- Price
- PDEX $42.23
- SLS $1.63
- Analyst Decision
- PDEX Strong Buy
- SLS
- Analyst Count
- PDEX 1
- SLS 0
- Target Price
- PDEX $56.00
- SLS N/A
- AVG Volume (30 Days)
- PDEX 45.3K
- SLS 2.9M
- Earning Date
- PDEX 05-01-2025
- SLS 05-13-2025
- Dividend Yield
- PDEX N/A
- SLS N/A
- EPS Growth
- PDEX 379.10
- SLS N/A
- EPS
- PDEX 2.76
- SLS N/A
- Revenue
- PDEX $64,123,999.00
- SLS N/A
- Revenue This Year
- PDEX $26.92
- SLS N/A
- Revenue Next Year
- PDEX $4.48
- SLS N/A
- P/E Ratio
- PDEX $15.21
- SLS N/A
- Revenue Growth
- PDEX 29.65
- SLS N/A
- 52 Week Low
- PDEX $16.84
- SLS $0.77
- 52 Week High
- PDEX $70.26
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- PDEX 42.91
- SLS 50.43
- Support Level
- PDEX $38.25
- SLS $1.36
- Resistance Level
- PDEX $43.66
- SLS $1.83
- Average True Range (ATR)
- PDEX 2.34
- SLS 0.17
- MACD
- PDEX 0.22
- SLS -0.03
- Stochastic Oscillator
- PDEX 42.12
- SLS 14.04
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.